UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
NCT02128230
Terminated
The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and 2006-66.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2021
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
NCT00378534
Completed
Bone marrow stem cell transplants (otherwise called bone marrow transplants) from healthy donors are sometimes the only means of curing hematological malignant diseases such as acute and chronic leukemias, myelodysplastic syndrome, myeloproliferative diseases and lymphomas. Before transplant the patient receives chemotherapy and radiation treatment to reduce the malignancy to low levels and to prevent rejection of the transplant. The transplant restores the blood counts to normal and replaces th... Read More
Gender:
ALL
Ages:
Between 10 years and 75 years
Trial Updated:
05/25/2021
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Register for Updates
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
NCT03885947
Completed
In this Phase I study, the study team will evaluate the safety of Valproic Acid (VPA) expanded cord blood stem cells defined by the lack of serious infusion reactions or graft failure in patients with hematological malignancies undergoing umbilical cord blood transplantation. Moreover, the study team will also evaluate time to neutrophil and platelet engraftment as well as transplant related outcomes such as graft versus host disease (GVHD), treatment related mortality (TRM), and overall surviva... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/20/2021
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Hematological Malignancy, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Register for Updates
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
NCT02413320
Completed
Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
05/06/2021
Locations: University of Kansas Cancer Center - CRC, Fairway, Kansas +8 locations
Conditions: Triple-negative Breast Cancer
Register for Updates
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
NCT00580333
Completed
The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor (ER) negative, Progesterone Receptor (PR) negative and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer. Cisplatin is used to destroy cancer cells in many types of cancers, and has shown to be effective and have manageable side effects. Bevacizumab i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2021
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Breast Cancer
Register for Updates
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
NCT00542191
Terminated
This neoadjuvant chemotherapy protocol focusing on "triple-negative" breast cancers alone will gather a foundation of primary tumor and axillary lymph nodal response to primary chemotherapy and ongoing correlated disease-free (DFS) and overall survival (OS) outcome data. This comparative data can then be used in building subsequent trials.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
05/04/2021
Locations: Brody School of Medicine at East Carolina University, Greenville, North Carolina
Conditions: Breast Cancer
Register for Updates
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
NCT03466320
Completed
This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients. This Phase I study will contain two different sequential segments. The first segment will determine the recommended investigational treatment option (schedule of preconditioning and NKR-2 dose) and the second segment will expand to a larger number of r/r AML/MDS patients.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/30/2021
Locations: University of Colorado, Aurora, Colorado +6 locations
Conditions: AML, MDS
Register for Updates
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
NCT01220128
Terminated
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2021
Locations: GSK Investigational Site, Newark, Delaware +35 locations
Conditions: Neoplasms, Breast
Register for Updates
Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
NCT03283202
Completed
This is Phase 1/2 study of avadomide (CC-122) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, for first-line treatment of patients with Diffuse B-Cell Large B-Cell Lymphoma (DLBCL) that has poor risk factors. Approximately 40% of patients diagnosed with DLBCL are not cured with R-CHOP alone and would need additional treatment for DLBCL in the future. The addition of the experimental drug avadomide (CC-122) with R-CHOP could help in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2021
Locations: George Washington University, Washington, District of Columbia +14 locations
Conditions: Diffuse B-Cell Lymphoma
Register for Updates
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
NCT00004067
Completed
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus trastuzumab is more effective than combination chemotherapy alone for treating breast cancer. PURPOSE: Th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2021
Locations: Comprehensive Cancer Institute, Huntsville, Alabama +148 locations
Conditions: Breast Cancer
Register for Updates
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02596971
Completed
This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment consisting of atezolizumab in combination with either obinutuzumab + bendamustine (Atezo-G-benda) or obinutuzumab + CHOP (Atezo-G-CHOP) in participants with FL and atezolizumab + rituximab + chemotherapy (Atezo-R-CHOP) in participants with DLBCL, followed by post-induction treatment consisting of either atezolizumab plus obinutuzumab (Atezo-G) in partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2021
Locations: Rocky Mountain Cancer Center - Aurora, Aurora, Colorado +20 locations
Conditions: Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Register for Updates
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
NCT00546156
Completed
Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment of ER+ or PR+ breast cancer. In this trial, the standard chemotherapy is being combined with bevacizumab. Bevacizumab is an antibody which works differently from the way other chemotherapy drugs work. Bevacizumab slows or stops cell growth in cancerous tumors by decreasing the blood supply to the tumors by binding... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2021
Locations: Massachusetts General Hospital, Boston, Massachusetts +3 locations
Conditions: Breast Cancer
Register for Updates